

Mismatch repair proteins in homologous recombination and genome stability

Diedre Reitz¹, John McPherson^{2,3}, Wolf-Dietrich Heyer^{1,2,4}

(1) Department of Microbiology and Molecular Genetics, College of Biological Sciences; (2) UC Davis Comprehensive Cancer Center; (3) Department of Biochemistry and Molecular Medicine, School of Medicine; (4) Department of Molecular and Cellular Biology

Mismatch repair proteins & cancer





Overview

- Mismatch repair proteins correct DNA polymerase misincorporation errors (Figure 5), and have a high mutational burden as a result.
- A subset of the mismatch repair proteins regulate the homologous recombination DNA repair pathway (Figure 6), but the contribution of loss of this regulation to tumorigenesis is unknown.
- Project goal is (1) to define the mechanism of regulation of homologous recombination by the mismatch repair proteins, and (2) to determine the contribution of loss of regulation of this pathway to carcinogenesis.

Therapeutic potential

- Most testing for mismatch repair deficiency in tumors involves antibody staining for the presence/absence of MSH2, MSH6, MLH1, and PMS1 (Figure 5).
- Database analysis (Figure 1) indicates that the majority of tumors with abnormalities in *MSH2* or *MSH6* have mutations or amplifications, which may not be detected via this method.
- MSH3* is another component of the mismatch repair pathway, and a regulator of homologous recombination. Though a significant fraction of certain tumor types have *MSH3* abnormalities (Figure 1), antibody testing for *MSH3* is not routine.

Figure 1. Frequency of *MSH2*, *MSH3*, and *MSH6* alterations across five of the most commonly affected cancer subtypes. Data from TCGA PanCancer Atlas Studies.



Specific aims

(1) Investigate the effect of heterologous flaps on the efficiency and timing of D-loop formation and extension.

- A 3-base pair flap decreased HR efficiency in a break-induced replication assay (3), but the effect of flaps on the canonical recombination pathway is unknown.
- MSH2-MSH3* promotes shorter D-loop extension tracts in response to flaps, preventing potential rearrangements (4, 5). How *MSH2-MSH3* achieve this effect is unknown.

A) Evaluate the effect of heterologous flaps on D-loop formation and extension *in vivo* in matched budding yeast strains using the DLC and DLE assays (Figure 3).

B) Use purified proteins to show that MSH2-MSH3 recognizes D-loops with terminal flaps *in vitro*, and reconstitute the mechanism of MSH2-MSH3 heteroduplex rejection.

(2) Define the mechanism of MSH2-MSH6-dependent heteroduplex rejection.

- Most studies on *MSH2-MSH6* and homeologous recombination examine recombination between a broken strand and a mismatched donor (6-9) (mismatch tolerance).
- Only study to examine recombination in the context of both a mismatched and a homeologous donor found <2X difference (10). However, their assay only detected very rare crossover products.

A) In a competitive system in which recombination can engage a mismatched or a homeologous donor, determine how MSH-MSH6 promotes use of the homeologous donor.

B) Use purified proteins to reconstitute MSH2-MSH6 heteroduplex rejection.

(3) Use long-read sequencing to determine whether MSH2 and MSH6 deficient tumors exhibit a mutational signature consistent with homeologous recombination.

- Site-specific studies in *Msh2*^{-/-} and *Msh6*^{-/-} mice found increased homeologous recombination in these backgrounds (11, 12).
- Mouse fibroblasts deficient in *Rtel1* (Figure 6) show increased structural variant breakpoints relative to wild-type cells (13).
- Findings suggest that heteroduplex rejection deficient cells harbor large-scale genome rearrangements.

References & funding

Diedre Reitz is supported by the Oncogenic Signals and Chromosome Biology NCI T32 training program (CA108459). Work in Wolf-Dietrich Heyer's laboratory is supported by the following grants: NCI R01 CA092276, NIGMS R01 GM058015, NIGMS R01 GM137751.

(1) Piazza et al. 2019 Mol Cell
 (2) Logsdon et al. 2020 Nature Reviews Genetics
 (3) Anand et al. 2017 Nature
 (4) Spell et al. 2004 Genetics
 (5) Chen et al. 1998 Mol. Cell Biol.
 (6) Datta et al. 1996 Mol. Cell Biol.
 (7) Sugawara et al. 2004 PNAS
 (8) Datta et al. 1997 PNAS
 (9) Hum et al. 2019 NAR
 (10) Nicholson et al. 2006 Genetics
 (11) de Wind et al. 1995 Cell
 (12) de Wind et al. 1999 Nature Genetics
 (13) León-Ortiz et al. 2018 Mol Cell